Although these findings may preclude the use of TFAM as a CpG-B enhancing vaccine adjuvant, TFAM may be useful for decreasing the pathogenic consequences of exposure to hypomethylated DNA in the context of trauma, autoimmune disease, or infection [8, 9, 26, 40, 41]. Here, TFAM is linked to autoimmune disease.